Key Takeaways from Agenus' Earnings Report
Shares of biotech Agenus (NAS: AGEN) appreciated almost 5% today, after the company posted its 3rd quarter earnings. The company's key compound, QS-21 Stimulon, is licensed to some of the biggest players in the pharmaceutical space, ,including GlaxoSmithKline (NYS: GSK) and Janssen, which is a subsidiary of Johnson & Johnson (NYS: JNJ) .
In the following video, health care analysts Max Macaluso and David Williamson discuss the company's latest quarter and a few things Agenus investors should watch.
Biotech companies can be some of the most exciting-and riskiest-investments on the market. However, it's essential to balance speculative plays in your portfolio with stocks that can help you build long-term weatlh. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you retire well, and also include some winning wealth-building strategies that every investor should know. Click here now to keep reading.
The article Key Takeaways from Agenus' Earnings Report originally appeared on Fool.com.Max Macaluso, Ph.D. and David Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying calls on Johnson & Johnson. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.